Nurul Syuhada Ishak1, Hanif Abdul Rahman2, Shirley H F Lee1, Shir Kiong Lu3, Lin Naing1. 1. PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong, BE1410, Brunei Darussalam. 2. PAPRSB Institute of Health Sciences, Universiti Brunei Darussalam, Jalan Tungku Link, Gadong, BE1410, Brunei Darussalam. hanif.rahman@ubd.edu.bn. 3. The Brunei Cancer Centre, Pantai Jerudong Specialist Centre, Bandar Seri Begawan, Brunei.
Abstract
INTRODUCTION: Oesophagogastric cancer is one of the leading causes of cancer death worldwide due to its aggressive nature. Despite the high mortality rate, there is limited information regarding this cancer in Brunei. AIM: To estimate the incidence and survival duration of oesophagogastric cancer patients, to identify prognostic factors of oesophagogastric cancer and associated factors for late-stage oesophagogastric cancer detection. METHODS: A retrospective study on all oesophagogastric cancer patients registered in the population-based national cancer registry in Brunei from January 2010 to December 2018. Kaplan-Meier and Cox proportional hazard regression survival analyses and multiple logistic regression were applied. RESULTS: Sixty-eight oesophagogastric cancer patients' data were retrieved from the registry. The incidence was 2.75 cases per 100,000 adults per year. Median survival time was 1.18 years (95% CI: 0.77, 1.80) and the 3-year survival rate was 26.3%. Age (61-70 years) (adjusted HR = 0.38; 95% CI: 0.17, 0.89; p = 0.025) and those who have undergone chemotherapy (adj. HR = 0.40; 95% CI: 0.18, 0.90; p = 0.026) have a significantly lower mortality risk. Obesity (adj. HR = 11.94; 95% CI: 1.94, 73.36; p = 0.007), and stage 4 (advanced stage) cancer (adj. HR=4.11; 95% CI: 1.97, 8.58; p< 0.001) have a significantly higher mortality risk. Females have 3-time odds (adj. OR = 3.05; 95% CI: 1.09, 9.02; p = 0.038) of presenting with stage 4 cancer. Smokers have 13-time odds (Adj. OR=12.99; 95% CI: 1.92, 262.0; p = 0.025) of presenting with stage 4 cancer. CONCLUSION: Prognosis of oesophagogastric cancer remains poor. Addressing late detection and improve endoscopic surveillance and awareness of symptoms may help improve prognosis and mortality.
INTRODUCTION: Oesophagogastric cancer is one of the leading causes of cancer death worldwide due to its aggressive nature. Despite the high mortality rate, there is limited information regarding this cancer in Brunei. AIM: To estimate the incidence and survival duration of oesophagogastric cancer patients, to identify prognostic factors of oesophagogastric cancer and associated factors for late-stage oesophagogastric cancer detection. METHODS: A retrospective study on all oesophagogastric cancer patients registered in the population-based national cancer registry in Brunei from January 2010 to December 2018. Kaplan-Meier and Cox proportional hazard regression survival analyses and multiple logistic regression were applied. RESULTS: Sixty-eight oesophagogastric cancer patients' data were retrieved from the registry. The incidence was 2.75 cases per 100,000 adults per year. Median survival time was 1.18 years (95% CI: 0.77, 1.80) and the 3-year survival rate was 26.3%. Age (61-70 years) (adjusted HR = 0.38; 95% CI: 0.17, 0.89; p = 0.025) and those who have undergone chemotherapy (adj. HR = 0.40; 95% CI: 0.18, 0.90; p = 0.026) have a significantly lower mortality risk. Obesity (adj. HR = 11.94; 95% CI: 1.94, 73.36; p = 0.007), and stage 4 (advanced stage) cancer (adj. HR=4.11; 95% CI: 1.97, 8.58; p< 0.001) have a significantly higher mortality risk. Females have 3-time odds (adj. OR = 3.05; 95% CI: 1.09, 9.02; p = 0.038) of presenting with stage 4 cancer. Smokers have 13-time odds (Adj. OR=12.99; 95% CI: 1.92, 262.0; p = 0.025) of presenting with stage 4 cancer. CONCLUSION: Prognosis of oesophagogastric cancer remains poor. Addressing late detection and improve endoscopic surveillance and awareness of symptoms may help improve prognosis and mortality.
Authors: G Buckland; N Travier; J M Huerta; H B As Bueno-de-Mesquita; P D Siersema; G Skeie; E Weiderpass; D Engeset; U Ericson; B Ohlsson; A Agudo; I Romieu; P Ferrari; H Freisling; S Colorado-Yohar; K Li; R Kaaks; V Pala; A J Cross; E Riboli; A Trichopoulou; P Lagiou; C Bamia; M C Boutron-Ruault; G Fagherazzi; L Dartois; A M May; P H Peeters; S Panico; M Johansson; B Wallner; D Palli; T J Key; K T Khaw; E Ardanaz; K Overvad; A Tjønneland; M Dorronsoro; M J Sánchez; J R Quirós; A Naccarati; R Tumino; H Boeing; C A Gonzalez Journal: Int J Cancer Date: 2015-02-13 Impact factor: 7.396
Authors: Robert Sitarz; Małgorzata Skierucha; Jerzy Mielko; G Johan A Offerhaus; Ryszard Maciejewski; Wojciech P Polkowski Journal: Cancer Manag Res Date: 2018-02-07 Impact factor: 3.989
Authors: Martin C S Wong; Willie Hamilton; David C Whiteman; Johnny Y Jiang; Youlin Qiao; Franklin D H Fung; Harry H X Wang; Philip W Y Chiu; Enders K W Ng; Justin C Y Wu; Jun Yu; Francis K L Chan; Joseph J Y Sung Journal: Sci Rep Date: 2018-03-14 Impact factor: 4.379